Prescribing information (external link)
The British Association of Dermatologists (BAD) Annual Meeting is an independently organised congress. Novartis Pharmaceuticals UK Ltd has provided sponsorship to the BAD congress. The congress is intended for UK healthcare professionals only. The symposium, Meet the Expert sessions and Evening Meeting are promotional meetings organised and funded by Novartis Pharmaceuticals UK Ltd, intended for UK healthcare professionals.
Join us at the 106th BAD Annual Meeting
Cosentyx® (secukinumab) is indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adults (alone or in combination with methotrexate [MTX]) who have responded inadequately to disease-modifying anti-rheumatic drug therapy; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy.1 Full indications can be found at the bottom of the page.
Discover our symposium and Meet the Expert sessions, and register to attend the third annual Dermatology Connect @ BAD Evening Meeting. With plenty of opportunities to learn and connect with peers. Find out more in the agenda below.
International Insights: Advancements in our Understanding of Psoriasis and Long-Term Joint Disease
Our UK Dermatology Evening Meeting at BAD
Join us for the third annual Dermatology Connect @ BAD Evening Meeting, bringing together leading experts in psoriatic disease to explore clinical experience in the management of skin and joint involvement.
Internationally recognised psoriasis experts Prof. Diamant Thaçi and Prof. Richard Langley will be joined by UK rheumatologist Prof. Pauline Ho to discuss the evolving landscape of psoriatic disease, offering complementary dermatology and rheumatology perspectives.
Agenda
-
15:00 15:25 Hrs
Meet the Expert | AI in Dermatology: Friend or FoeDr. Maria-Angeliki Gkini -
11:00 11:25 Hrs
Meet the ExpertProf. Diamant Thaçi15:00 15:25 Hrs
Meet the Expert | Treat-to-target in Hidradenitis SuppurativaProf. John Ingram13:00 14:00 Hrs
BAD Symposium | Innovation in Immunology: The Next ChapterProf. Richard Warren, Prof. Richard Langley, Dr. Maria-Angeliki Gkini19:15 20:00 Hrs
DermatologyConnect@BAD Evening Meeting | International InsightsProf. Diamant Thaçi, Prof. Richard Langley, Prof. Pauline Ho -
07:30 17:30 Hrs
Visit our stand – Novartis team
Curious about our symposium?
Innovation in Immunology: The Next Chapter
Skin to Joints: Rethinking Early Intervention
Our expert panel will explore current approaches to the management of psoriatic disease, with a focus on the importance of earlier recognition and timely intervention to support improved patient outcomes. Hear from Prof. Richard Warren, Prof. Richard Langley and Dr Maria‑Angeliki Gkini as they share clinical insights and discuss evolving strategies in psoriatic disease management. Join us in exhibition hall 2.3 to learn more.
Register now to secure your spot at the Evening Meeting on 1 July 2026
This is a promotional meeting organised and funded by Novartis Pharmaceuticals UK Ltd., for UK healthcare professionals only.
Please note that this Evening Meeting is at The Manchester Deansgate Hotel, 303 Deansgate, Manchester, M3 4LQ, and not within the convention complex.
Therapeutic Indications1
Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.1
AS, ankylosing spondylitis; BAD, British Association of Dermatologists; ERA, enthesitis-related arthritis; HS, hidradenitis suppurativa; JPsA, juvenile psoriatic arthritis; MTX, methotrexate; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; PsO, plaque psoriasis.
Reference
Cosentyx® (secukinumab) Summary of Product Characteristics.
UK | May 2026 | FA-11634983
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
